“I think the main point is that this is a rare problem,” said Dr. Martin Blaser, director of Rutgers Center for Advanced Biotechnology and Medicine and an investigator on the university’s Johnson & Johnson vaccine trial.
“We have many drugs with risks of serious complications much greater than this one,” said Blaser, also a professor of medicine. “Non steroidal anti-inflammatory medication, people can get fatal problems with that, but they’re very rare. And that’s why we’re able to use them.”